Document:

<PAGE>

                                   SCHEDULE B
                          EXCLUSIVE LICENSING AGREEMENT

THIS AGREEMENT made by and between the parties herein below, to wit:

As Parties of the First Part:

         STEROIDOGENESIS INHIBITORS, INC., a Corporation incorporated under the
         laws of the State of Nevada, and having its principal office and place
         of business at 2001 E. Flamingo Blvd., Suite 100-B, Las Vegas, Nevada
         89119, USA (hereinafter simply called "SI"), and DR. ALFRED T. SAPSE,
         (hereinafter simply called "SAPSE") (SI and SAPSE collectively referred
         to as the "Developers")

As a Party of the Second Part:

         STEROIDOGENESIS INHIBITORS CANADA INC., a Corporation incorporated
         under the laws of the Province of Alberta, Canada, and having its
         principal office and place of business at Suite 1002, Park Plaza, 10611
         - 98 Avenue, Edmonton, Alberta, T5K 2P7, Canada, herein represented by
         its Director President, Ms. Anne Ryan (hereinafter simply called "SI
         Canada").

WHEREAS:

1. SI is engaged in the development, manufacture and sales of certain
   pharmaceutical products, having successfully developed a product designated
   ANTICORT, for AIDS treatment, including all technical knowledge necessary for
   its production in commercial scale;

2. SI Canada is engaged in the marketing of medical hospital, dental and
   laboratory products and is capable of carrying out the marketing of ANTICORT;

3. SI Canada is desirous of obtaining an exclusive license to manufacture, use,
   distribute and sell ANTICORT;

<PAGE>

NOW THEREFORE, in consideration of mutual covenants and agreements herein
contained, the Parties have agreed as to a license based on the following
clauses and conditions:

1 INTERPRETATION

1.1 Definitions

    Unless otherwise stated, in this Agreement:

    1.1.1 "Agreement" means this technology license agreement, together with any
          amendments to or replacements of this technology license agreement;

    1.1.2 "Effective Date" means the 10th day of February, 1996;

    1.1.3 "Improvements" shall mean any future improvements, innovations,
          inventions, modifications, designs, plans, drawings, specifications,
          techniques, processes, data and technical information, whether
          patented or unpatented, made or acquired by the Developers during the
          term of this Agreement relevant to the use of, or the manufacture of
          the Products;

    1.1.4 "Methods and Technical Know-how" shall mean all information,
          processes, knowledge and experience of a technical and commercial
          nature, including trade secrets and the Specifications relating to
          techniques for the use of, or methods of or practices in the use of,
          or the manufacture of the Products;

    1.1.5 "Parties" means the Developers and SI Canada;

                                      -2-
<PAGE>

    1.1.6 "Patent Rights" means all issued patents, as well as any pending
          applications and includes all reissues, renewals, extensions,
          divisions, continuations and continuations-in-part related thereto,
          wherever filed or obtained, covering the Technology or the Products or
          any method, technique or process which may be practiced using the
          Technology or the Products. A list of all issued patents and pending
          applications as at the Effective Date is set forth in Schedule A;

    1.1.7 "Products" shall mean ANTICORT and any cortisol treatment related
          products developed by the Developers as Improvements;

    1.1.8 "Proprietary Information" means any information, including know-how,
          show-how, confidential and other trade secret information, developed
          or owned by the Developers relating to the design, manufacture,
          operation or use of the Technology or the Products and not generally
          known to others in the industry or readily ascertainable by proper
          means which gives the Products an advantage over other competitors.
          Proprietary Information shall not include information which:

          (a) at the time of its disclosure is already part of the public
              knowledge;

          (b) after disclosure hereunder, becomes part of the public knowledge
              by publication or otherwise through no fault of SI Canada;

          (c) prior to the time of disclosure hereunder, was received by SI
              Canada in writing from a third party who had a lawful right to
              disclose it and who did not require SI Canada to hold it in
              confidence; or

          (d) after the time of disclosure hereunder was received by SI Canada
              in writing from a party who had a lawful right to disclose it and
              who did not require SI Canada to hold it in confidence.

                                      -3-
<PAGE>

    1.1.9  "Proprietary Marks" means ANTICORT and any other trade names,
           trade marks and other commercial symbols established by SI related to
           the Products or the Technology from time to time;

    1.1.10 Specifications" shall mean all specifications, methods, applications,
           technical data, drawings, adjustment, calibration and testing
           procedures, criteria, qualities, requirements and all other
           information in connection with the use of the Technology or the
           manufacture of the Products published or promulgated by or for the
           benefit of SI and its licensees, manufacturers, distributors and
           vendors including any manual, specification booklet, letter, notice,
           memorandum or other written form from time to time;

    1.1.11 "Technology" means all property forming part of, or existing or
           arising as a result of, the Patent Rights, the Methods and Technical
           Know-how, the Proprietary Information, the Specifications and any
           Improvements;

    1.1.12 "Territory" means Canada, such of the member nations of the British
           Commonwealth as have been added to the Territory from time to time
           pursuant to Section 2.3 and any other country in respect of which SI
           agrees to grant SI Canada the license contained in this Agreement.

1.2 Extended Meaning

    All words importing the singular number shall include the plural and the
plural the singular, and all references to gender shall include the male, female
and neuter, as the context shall require or imply. A reference to dollars, "$"
or amounts of money means lawful money of the United States.

                                      -4-

<PAGE>

1.3 Articles and Headings

    The division of this Agreement into articles and sections and the insertion
of headings are for convenience of reference only and shall not affect the
construction or interpretation hereof. A reference to an article or a section
number shall, unless otherwise stated, be a reference to an article or section
of this Agreement.

1.4 Meaning of Expressions

    "Herein", "hereof" or "hereunder" and similar expressions when used in a
section shall be construed as referring to the whole Agreement and not that
section only.

1.5 Schedules

    Any schedules attached to this Agreement shall form part of this Agreement.

2 GRANT OF LICENSE

2.1 Authority

    The Developers represent that SI is the owner of the Technology, has the
right to license the Technology in the Territory and has not granted to any
other person any rights forming part of the Technology in relation to the
Territory or any part thereof. SAPSE agrees not to take any steps related to the
Technology which would cause SI to be unable to fulfill its obligations under
this Agreement.

2.2 SI hereby grants to SI Canada, effective from the Effective Date and
continuing throughout the term of this Agreement, the exclusive right and
license, upon the terms and

                                      -5-

<PAGE>

conditions herein specified, to manufacture, use, distribute and sell the
Products in the Territory, and in connection therewith to use all Technology.
Without limiting the generality of the foregoing:

    (a) the licenses granted herein shall not authorize SI Canada to act as the
        agent or the attorney in fact of the Developers or either of them, and

    (b) the exclusivity rights granted shall prevent the Developers or any
        person claiming under them other than SI Canada from manufacturing,
        using distributing or sell the Products in the Territory.

2.3 At any time and from time to time within one year from the Effective Date,
SI Canada shall have the option to expand the Territory to include, in addition
to Canada, any other country, still available for contractual agreement, which
was a member of the British Commonwealth as at the Effective Date. Such option
may be exercised by notice to SI of the name of the country to be included in
the Territory accompanied by a deposit of $10,000. The total amount payable to
SI for the licenses and rights for any country added to the Territory by SI
Canada will be the applicable amount stated in Section 4.2. The expansion of the
Territory shall be effective as of the date of notice to SI.

2.4 In the event that SI receives a bona fide written offer from a third party
to purchase the license rights for any country or countries which are subject to
the option rights of SI Canada set out in Section 2.3, SI will have the right to
give written notice to SI Canada (including all terms of the written offer) to
exercise its option regarding that country or those countries within forty-five
(45) days, failing which SI will be at liberty to sell the license to the third
party according to and only according to the terms of the written offer. The
price payable by SI Canada in the event SI Canada chose to exercise its option,
will be the lesser of the price established by Section 4.2 and the price
contained in the third party offer. The appropriate price will be payable on the
set terms and conditions as were contained in the written offer.

                                      -6-

<PAGE>

2.5 SI shall forthwith advise SI Canada in writing, of the sale by SI of a
license related to the Technology for any country including all countries not
subject to the option.

2.6 Distributors and Sub-manufacturers

    Subject to the following requirements, SI Canada shall have their right to
sub-license its rights to manufacture, market, develop and use the Technology
and the Products in the Territory and to appoint distributors and
sub-manufacturers of the products:

    (a) SI Canada shall not sub-license its rights or appoint any distributor or
        sub-manufacturer until it has entered into an agreement with the
        sub-licensee, distributor or sub-manufacturer containing terms and
        conditions relating to the use and protection of Proprietary Information
        and the Technology which are substantially the same as the terms and
        conditions of this Agreement; and

    (b) in the event of a violation by a sub-licensee, distributor or
        sub-manufacturer of the terms and conditions of an agreement relating to
        the use and protection of Proprietary Information, SI Canada shall
        immediately notify SI thereof and SI shall, on request of SI Canada and
        to the extent permitted by law, be entitled to participate with SI
        Canada in enforcing any cause of action SI Canada may have in respect of
        the alleged violation.

SI Canada will be responsible at its expense for preparing and processing any
registration it considers desirable to protect its exclusivity related to the
Technology in the Territory. The Developers shall promptly execute all documents
reasonably necessary to be executed by the owners (or inventors) of the
Technology. SI Canada shall have no liability related to any failure on its part
to obtain any registration required to protect the Technology or any part
thereof from use by others. Nothing in this Section shall restrict the rights of
the

                                      -7-

<PAGE>

3 DURATION

3.1 Subject to earlier termination as provided in this Agreement, the licenses
and rights granted to SI Canada pursuant to this Agreement shall continue from
creation until the date which is ten (10) years after the date on which the
Products have first received all approvals from the appropriate Canadian
government authorities required for the sale of the Products as pharmaceutical
products in Canada. The licenses and rights granted to SI Canada for any country
which forms part of the Territory on the expiry date of the initial term of this
Agreement and in which SI Canada (or its sub-licensees or sub-manufacturers or
distributors) continues to distribute and sell the Products shall be
automatically renewed for a further period of ten (10) years.

4 LICENSE FEES AND ROYALTIES

4.1 The total compensation payable by SI Canada to SI for the licenses and
rights granted to SI Canada for Canada pursuant to this Agreement shall be a fee
of $200,000, the receipt of which SI acknowledges and the royalty described in
Section 4.3.

4.2 The total compensation payable by SI Canada for any country added to the
Territory pursuant to Section 2.3 will be whichever of the following fees is
applicable:

    (a) for Great Britain                      $150,000
    (b) for any other country                  $200,000 or any lesser
                                                amount specified pursuant to the
                                                application of Section 2.4

                                      -8-

<PAGE>

(provided that there will be deducted from the first country added to the
Territory pursuant to Section 2.3 the sum of $30,000) and the royalty described
in Section 4.3.

4.3 In addition to the fixed fees referred to in Sections 4.1 and 4.2, SI Canada
will pay a variable fee equal to ten (10%) percent of the "manufacturing value"
of the sales of Products effected by SI Canada in the Territory. The
"manufacturing value" will be the price charged by SI Canada to wholesalers for
Products manufactured by or on behalf of SI Canada, excluding any taxes required
to be collected or charged by SI Canada in relation to such sale, which will
ultimately be sold in the Territory.

4.4 This variable fee will be payable on the 20th day of April, July, October
and January of each year and each quarterly payment shall include payment in
respect of all sales to wholesalers made in the prior quarter.

4.5 Where any sale is made and SI Canada either is unable to recover payment for
Products delivered or subsequently refunds payment due to a problem with the
Products delivered, the sale will not be included for the purposes of
calculating the variable fee payable and, where payment of the variable fee has
already been made relative to that sale, appropriate adjustments will be made on
the quarterly account next following the write-off of the receivable or the
making of the refund, as they case may be.

4.6 Where a sale is in a currency other than United States dollars, the
"manufacturing value" for that sale will be converted to United States dollars
using the exchange rate quoted by the Royal Bank of Canada on the business day
next following the date of SI Canada's invoice to the wholesaler for the sale.

5 SI'S OBLIGATIONS

5.1 SI will:

                                      -9-
<PAGE>

(a) supply to SI Canada the Specifications, including without limitation the
    formula for the Products and all the technical knowledge necessary for the
    production of the Product and further including laboratory test results,
    experimental animal tests, clinical use in patients, manufacturing data and
    manufacturing secrets, as well any Improvements free from any additional
    remuneration besides that already provided for in his Agreement;

(b) supply technical assistance to any physicians and researchers utilized by SI
    Canada for clinical tests of the Products in Canada or other countries in
    the Territory, all in accordance with the parameters of the World Health
    Organization (WHO);

(c) supply quantities of the Products sufficient for the making of clinical
    studies by SI Canada in Canada and other countries in the Territory;

(d) supply technical assistance to SI Canada as required to satisfy the
    requirements of competent health related government departments or
    ministries in the Territory;

(e) supply, whenever requested by SI Canada, on at least thirty (30) days prior
    notice, the service of SAPSE for appearances in the Territory for
    interviews, for meetings with scientists, for lectures to the health
    authorities, press media, etc. SI Canada will be responsible for all travel
    expenses and a per diem fee of One Thousand United States Dollars (US
    $1,000). Such services shall not exceed more than two (2) days per month,
    unless expressly agreed otherwise by the parties;

(f) supply, whenever requested by SI Canada, and within the reasonable
    availability of SI's technical team, technical assistance in the Territory
    with payment of all travel expenses and a fee of Four Hundred United States
    Dollars (US $400) per man per day;

                                      -10-
<PAGE>

(g) all reasonable technical assistance and co-operation from the Developers,
    including without limitation proper completion and execution of applications
    for patents and trade marks, required to obtain available protection of the
    Technology in any country in the Territory.

5.2 If, for reasons not attributable to SI Canada, the Technology cannot be
protected by appropriate registrations in any country included in the Territory
and if as a result SI Canada is not able to enjoy exclusive rights to the
manufacture, use, distribution or sale of the Products in that country, SI
Canada may terminate the license in relation to that country by notice to SI. In
that circumstance SI will refund any fixed fees paid in relation to such license
pursuant to Sections 4.1 and 4.2 and will also assume all the expenses of such
termination.

6 OBLIGATIONS OF SI Canada

6.1 SI Canada shall:

    (a) be responsible for the making, at its expense, of all clinical testing
        and documentation required to obtain all approvals required to sell the
        Products in a country in the Territory by the competent governmental
        authorities (the approvals in each country being referred to as the
        "Approval") in the shortest period of time practicable, keeping SI
        informed on the proceedings and conclusion of all such tests and
        approval of the Products;

    (b) when an Approval is obtained, begin, within ninety (90) days of the
        obtaining of the Approval, the production of the Products in accordance
        with the quality standards prevailing in the pharmaceutical industry in
        the country in question and in compliance with the Specifications
        supplied by SI;

                                      -11-

<PAGE>

    (c) maintain accurate books and records relating to the production,
        packaging, and shipment of Products, the rejection of Products and the
        non-payment of Products, as well as any other records required to be
        maintained by applicable laws or hereunder and shall retain all such
        records for a period of at least four (4) years;

    (d) prepare and submit to SI, monthly quality control reports as required
        herein;

    (e) maintain updated records, authorizations, and licenses required by
        Canadian and foreign legislation for the production and distribution of
        the Products in the Territory, including ensuring that the appropriate
        licenses are maintained in good standing by any distributors that SI
        Canada may retain in any countries within the Territory; and

    (f) promote, at its own expense and to the reasonable satisfaction of SI,
        the sale of the Products throughout the Territory, including:

          (i) exposing the Products to the medical community and the public and
              private entities connected with public health,

         (ii) advertising and promoting the sale of the Products and making
              regular and sufficient contact with the present and future
              customers of the Products in the Territory, and

        (iii) maintaining adequate sales and warehouse facilities and a
              sufficient stock of Products to ensure prompt delivery to
              customers.

                                      -12-

<PAGE>

7 ACCESS TO SI CANADA'S AND DISTRIBUTOR'S PREMISES

7.1 At all reasonable times and on reasonable prior notice during the term of
this Agreement, SI's representatives shall be permitted free access to the
premises of SI Canada, its distributors and subcontractors, for inspection
purposes so that SI may ascertain whether the production, handling, and storage
of the Products are being correctly performed in accordance with the provisions
of this Agreement.

8 INDEMNIFICATION WARRANTIES

8.1 SI Canada shall indemnify SI for any costs, expenses, claims or liabilities
that the latter may incur as a result of any breach of this Agreement or
negligence by SI Canada, its directors, employees or representatives. SI shall
immediately communicate to SI Canada notice of any claim or proceeding, whether
by court proceedings or otherwise, that may result in civil liability to SI and
SI Canada shall, on posting security reasonably sufficient to protect SI
relative to such claim or proceeding, be entitled to assume control of the
defence and settlement of such claim or proceeding.

8.2 SI shall indemnify SI Canada for any costs, expenses, claims or liabilities
that the latter may incur as a result of any breach of this Agreement or
negligence by SI, its directors, employees or representatives. SI Canada shall
immediately communicate to SI notice of any claim or proceeding, whether by
court proceedings or otherwise, that may result in civil liability to SI Canada
and SI shall, on posting security reasonably sufficient to protect SI Canada
relative to such claim or proceeding, be entitled to assume control of the
defence and settlement of such claim or proceeding.

                                      -13-

<PAGE>

9 USE OF THE TRADEMARK ANTICORT

9.1 While this Agreement is effective, the Products shall always be marketed
under the trademark ANTICORT, which is currently under registration in the
United States of America, and the registration of which in Canada and the other
nations in the Territory shall be undertaken by SI or such other Proprietary
Marks as are being used generally by SI in relation to the Products. SI Canada
shall indicate on the label of every unit of the Products sold that it is
produced under license from SI.

9.2 SI Canada shall refrain from using or permitting its distributors to use any
Proprietary Marks as though owned by it or them. The foregoing shall not prevent
SI Canada or its authorized distributors from advertising the Products and in
connection therewith using the Proprietary Marks then generally being used by
SI.

10 TERMINATION

10.1 SI shall have the right to terminate this Agreement and the rights and
licences granted hereunder, without prejudice to SI's right to rely on any other
legal right or remedy, if any of the following events of default occur:

     (a) if either SI Canada

         (i)  defaults in the due and punctual payment of any amount payable
              under this Agreement, when and as due; or

         (ii) breaches any of the other terms or conditions of this Agreement;
              and

                                      -14-

<PAGE>

              if in either event the default or breach continues for a period of
              45 days after written notice has been given to SI Canada by SI
              requesting that the default or breach be remedied, or:

     (b) if SI Canada makes or purports to make a general assignment for the
         benefit of creditors or any proceedings are instituted under any
         statute relating to insolvency, or bankruptcy of SI Canada, or if a
         custodian, receiver, manager, trustee or any other person with like
         powers is appointed to take charge of all or any part of SI Canada's
         undertaking, business, property or assets.

11 OBLIGATIONS FOLLOWING TERMINATION

11.1 Upon termination of this Agreement for any reason whatsoever, SI Canada
shall:

     (a) return to SI all confidential or propriety business or technical
         material relating to the Products,

     (b) cease using SI's Proprietary Marks and thereafter refrain from holding
         SI Canada out as a producer or distributor for the Products, and

     (c) comply with the confidentiality obligation prescribed by clause 18 for
         a minimum of three (3) years after the date of termination.

12 GOVERNING LAW

12.1 This Agreement shall be made and construed in accordance with the laws of
Alberta and of Canada and, to decide any dispute that may not be amicably
settled by the Parties, the competent civil court of the Province of Alberta is
hereby chosen.

                                      -15-

<PAGE>

13 ENFORCEABILITY

13.1 It is agreed that should any clause of this Agreement be unenforceable or
prohibited by law or by any court or tribunal decision, the other clauses and
conditions shall be valid and enforceable. In the event such court decision
involves a partial alteration of any provision hereof, then such clause shall be
amended, and is hereby amended, so as to be in compliance with the said
legislation or court decision, without prejudice to the other clauses and
conditions, which will remain valid and enforceable.

14 COMPLIANCE WITH LOCAL LAWS

14.1 SI Canada shall perform its obligations hereunder in full compliance with
applicable local laws and regulations. SI Canada shall be responsible for any
non-compliance of the Products with any local laws and regulations, SI Canada
shall be responsible for notifying SI, as soon as reasonably possible after
becoming aware of the same, of any laws or regulations, whether in effect or
proposed, which may adversely affect the obligations and the rights of SI or SI
Canada or the sale of the Products in the Territory.

15 NO ASSIGNMENT

15.1 SI Canada shall be entitled to contract with public or private research
institutes or organizations to conduct the clinical trials and research
necessary to obtain all approvals of the Products required, as well as with
foundations of national renown and governments for the due sponsorship and
financing of such trials and research, but shall remain in any event always
responsible to SI with respect to the faithful performance of this Agreement.
Subject to Section 2.6, SI Canada cannot assign this Agreement to any other
person without the prior approval to such assignment by SI which approval shall
not be unreasonably or arbitrarily withheld.

                                      -16-

<PAGE>

16 AMENDMENTS

16.1 This Agreement cannot be amended or altered except by a written instrument
signed by the Parties. All waivers of any rights under this Agreement must also
be in writing and will only apply to the extent specified.

16.2 If any of the Parties believe the Agreement should be amended to further
the mutual obligations of the parties, it may advise the others of any changes
proposed and upon receipt of such a proposal, the Parties agree to discuss the
same in good faith.

17 NOTICES

17.1 Any notice or notification, order, instruction or other document to be
delivered or supplied pursuant to the terms hereunder shall be in writing and
shall be deemed to have been given if personally delivered or mailed by prepaid
registered mail or faxed to:

     If to SI or SAPSE, when addressed to:
             2001 E. Flamingo Blvd., Suite 100-B
             Las Vegas, Nevada 89119
             U.S.A.
             Attention: Dr. Alfred T. Sapse, President
             Fax:(702) 737-7016

     If to SI Canada, when addressed to:
             Suite 1002, Park Plaza
             10611 - 98 Avenue
             Edmonton, Alberta
             T5K 2P7, Canada
             Attention: Mrs. Anne Ryan, President
             Fax: (403) 922-4489

                                      -17-

<PAGE>

17.2 Any notice delivered personally shall be deemed to be received when left
during normal business hours at the address specified above, any notices sent by
prepaid registered mail shall be deemed to have been received on the third (3)
business day following posting and any notice sent by fax will be deemed to be
received on the next business day. Either party shall be entitled to change its
address for notice to such other address as may be substituted from time to time
by notice in writing to the other.

18 FORCE MAJEURE

18.1 Neither Party shall be liable to the other for any failure to perform or
delay in the performance of, its obligations hereunder, nor be deemed to be in
breach of this Agreement if such failure or delay has arisen from "Force
Majeure". "Force Majeure" means circumstances and conditions beyond the control
of the party affected thereby which render it impossible for such party to
fulfill its obligation under this Agreement or which will delay such
fulfillment. Force Majeure shall include, but not be limited to, the following
matters: war; acts of foreign enemy; civil war; earthquake; flood, fire or other
natural physical disaster, strike or lock-out. Shortages of labour, materials,
transportation or utilities shall not constitute Force Majeure unless caused by
circumstances which are themselves Force Majeure. Lack of finances or inability
to perform because of the financial condition of a party shall not constitute
Force Majeure.

18.2 If either Party is prevented from, or delayed in, performing any of its
obligations under this Agreement by Force Majeure, such party shall as soon as
possible notify the other party of the circumstances constituting Force Majeure
and of the obligations the performance of which will thereby be delayed or
prevented and the party giving the notice shall thereupon be excused the
performance or punctual performance, as the case may be, of such obligations for
the period of time directly attributable to such prevention or delay.

                                      -18-

<PAGE>

19 CONFIDENTIALITY

19.1 SI Canada undertakes to maintain all Proprietary Information strictly
confidential, and shall not reveal Proprietary Information to third parties,
except and to the extent required by law or by court decision, or as necessary
to enable SI Canada, its employees, subcontractors and sub-licensees to perform
obligations under this Agreement or to manufacture, use, distribute or sell the
Products within the Territory.

19.2 SI Canada shall procure from its employees, subcontractors and
sub-licensees written commitments whereby they will undertake to abide by this
confidentiality obligation.

     Being thus in full agreement, the Parties cause this Agreement to be
executed in four (4) counterparts of equal tenor, by their duly authorized legal
representatives.

In Las Vegas, Nevada:
Date: February 10, 1996
      -----------------------------------------

STEROIDOGENESIS INHIBITORS, INC.

Per: /s/ Alfred T. Sapse
    -------------------------------------------
    Alfred T. Sapse, M.D., President

ALFRED T. SAPSE

In Edmonton, Alberta:
Date: February 10, 1996
      -----------------------------------------

STEROIDOGENESIS INHIBITORS CANADA INC.

Per: /s/ Anne Ryan
     ------------------------------------------
     Anne Ryan, President

                                      -19-

<PAGE>

                                Agreement Between

THIS AGREEMENT made by and between the parties herein below, to wit

                     STEROIDOGENESIS INHIBITORS CANADA INC.

Suite 1002, Park Plaza, 10611 - 98 Avenue, Edmonton, Alberta, T5K 2P7, Canada -
                        (herein simply called SI Canada)

                                       AND

                         STEROIDOGENESIS INHIBITORS INC.
        2001 E Flamingo Blvd., Suite 100B, Las Vegas, Nevada, 89119, USA
                         (Hereinafter simply called SI)

WHEREAS: SI Canada has not, on the date below, finalized its payment for license
to SI, the following terms, which the above parties agreed to, will apply:

1. Not withstanding the signatures of a certain Schedule B "Exclusive Licensing
   Agreement" between SI and SI Canada of February 10, 1996, SI Canada would pay
   to SI the amount of US $90,000 still owed by SI Canada to SI on or before
   March 31, 1996. Failure to pay these funds by March 31, 1996 will invalidate
   the whole and entire Schedule B "Exclusive Licensing Agreement".

2. Upon final payment, SI (Sapse) will release the Specifications, Improvements,
   Methods and Technical Know-how, Proprietary Information, and Technology to SI
   Canada who will hold these items in a secured location, in accordance with
   the non-disclosure terms stated in the licensing agreement, until they are
   required for Product production.

Date February 10, 1996

Steroidogenesis Inhibitors Canada Inc.       Steroidogenesis Inhibitors Inc.

Per: /s/ Anne Ryan                               Per: /s/ Alfred T. Sapse
     ---------------------------------            ----------------------------
     Anne Ryan, President                         Dr. Alfred T. Sapse, President

<PAGE>

                                    AGREEMENT

                                     between

As parties to the first part:

          STEROIDOGENESIS INHIBITORS INC., a Corporation incorporated under the
          laws of the state of Nevada, having its principal office and place of
          business at 2001 E. Flamingo Blvd., Suite 100-B, Las Vegas, Nevada,
          89119, USA (hereinafter called "SI") and DR. ALFRED T. SAPSE,
          (hereinafter called "SAPSE"). (SI and SAPSE collectively referred to
          as the "Developers")

                                       and

As parties of the second Part:

          STERIODOGENESIS INHIBITORS CANADA INC., a Corporation incorporated
          under the laws of the Province of Alberta, Canada, and having its
          principal office and place of business at Suite #48, 240 - Baseline
          Road, Sherwood Park, Alberta, T8H IS8, Canada, herein represented by
          its Director, President and CEO, Mr. Warren Jackson (hereinafter
          simply called "SI Canada").

WITH REFERENCE to:

                                  AMENDMENT TO

                    SCHEDULE B, EXCLUSIVE LICENSING AGREEMENT
                    "Effective Date, 10th of February, 1996"

THIS AGREEMENT made by and between the parties herein below to wit:, that in
consideration of this Amendment, it is agreed that:

1. SI Canada will pay to SII, $50,000.00 USD, (fifty thousand dollars), upon
   the signing of the Amendment to the Schedule B, Exclusive Licensing
   Agreement, "Effective Date, 10th of February, 1996".

                                     1 of 2

<PAGE>

2. SI Canada will pay to SI, an additional payment of $50,000.00 USD, (fifty
   thousand dollars), this payment to be "Payment in Full", five to ten business
   days after SI Canada is a Publicly Traded Company, trading on the Alberta
   Stock Exchange. Failure to do so, will bring about the cancellation of the
   AMENDMENT to SCHEDULE B, EXCLUSIVE LICENSING AGREEMENT, effective date 10th
   of February, 1996, between SI Canada and SI, USA.

3. England, New Zealand, Australia and Brienic are four countries exempt from
   the Commonwealth Countries referred to in Section 2.3 of SCHEDULE B,
   EXCLUSIVE LICENSE AGREEMENT, Dated 10th of February, 1996, as an optional
   country for inclusion into the Territory of SI Canada.

4. SI will provide to SI Canada a signed letter, on SI letterhead, stating the
   approximate dollar value spent to date on the development of ANTICORT up to
   the IND Approval to test stage.

5. SI will provide to SI Canada proof of Patent or Patent Pending protection in
   the various countries applied for.

   Being this in full agreement, the parties cause this Agreement to be executed
   in four (4) counterparts of equal tenor, by their duty authorized legal
   representatives.

   In Las Vegas, Nevada, Dated: July 7, 1997,

   STERIODOGENESIS INHIBITORS INC.

   Per:  /s/ Alfred T. Sapse
        ----------------------------------------
        Alfred T. Sapse, M.D., President

   STERIODOGENESIS INHIBITORS CANADA INC.

   Per: /s/ Warren Jackson
        ----------------------------------------
        Warren Jackson, President & CEO

                                     2 of 2

<PAGE>

                                  AMENDMENT TO
                                   SCHEDULE B

                          EXCLUSIVE LICENSING AGREEMENT
                    "Effective Date, 10th of February, 1996"

THIS AGREEMENT made by and between the parties herein below to wit:

As parties to the first part:

          STEROIDOGENESIS INHIBITORS INC., a Corporation incorporated under the
          laws of the state of Nevada, having its principal office and place of
          business at 2001 E. Flamingo Blvd., Suite 100-B, Las Vegas, Nevada,
          89119, USA (hereinafter called "SI") and DR. ALFRED T. SAPSE,
          (hereinafter called "SAPSE"). (SI and SAPSE collectively referred to
          as the "Developers")

As parties of the second Part:

          STERIODOGENESIS INHIBITORS CANADA INC., a Corporation incorporated
          under the laws of the Province of Alberta, Canada, and having its
          principal office and place of business at Suite #48, 240 - Baseline
          Road, Sherwood Park, Alberta, T8H 1IS8, Canada, herein represented by
          its Director, President and CEO, Mr. Warren Jackson (hereinafter
          simply called SI Canada").

                            AMENDMENT TO SECTION 2.3

IT IS AGREED that section 2.3 of this agreement be amended to:

2.3 At any time from time to time within one year from the date of the drug
approval, SI Canada shall have the option to expand the Territory to include, in
addition to Canada, any other country still available for contractual agreement
which was a member of the British Commonwealth as at the Effective Date. Such
option may be exercised by notice to SI of the name of the country to be
included

                                     1 of 2

<PAGE>

in the Territory accompanied by a deposit of $10,000. The total amount payable
to SI for the licenses and rights for any country added to the Territory by SI
Canada will be the applicable amount stated by Section 4.2 The expansion of the
Territory shall be effective as of the date of notice to SI.

Being this in full agreement, the parties cause this Amendment to be executed in
four (4) counterparts of equal tenor, by their duly authorized legal
representatives.

In Las Vegas, Nevada:

Date: July 7, 1997
      ---------------------------------------
STERIODOGENESIS INHIBITORS INC.

 Per:  /s/ Alfred T. Sapse
        ----------------------------------------
        Alfred T. Sapse, M.D., President

ALFRED T. SAPSE

STERIODOGENTESIS INHIBITORS CANADA INC.

   Per: /s/ Warren Jackson
        ----------------------------------------
        Warren Jackson, President & CEO

WARREN JACKSON

                                     2 of 2<PAGE>

                              CONSULTING AGREEMENT

                  THIS CONSULTING AGREEMENT (hereinafter "Agreement") is made
this 15th day of July, 1998, by and between Performance Strategies, Inc., a
Colorado corporation (hereinafter "Consultant"), whose principal place of
business is 9861 Titan Park Circle, Littleton, Colorado 80125 USA, and
Steroidogenesis Inhibitors International, (hereinafter "Client"), whose
principal place of business is 2001 E. Flamingo Blvd., Suite 100B, Las Vegas, NV
89119.

                                    RECITALS

                  WHEREAS, Consultant is willing and capable of providing, on a
"best efforts" basis, various consulting and financial public relations services
for and on behalf of Client in connection with Client's interactions with
broker-dealers, shareholders and members of the general public (collectively
herein, the "Services"); and

                  WHEREAS, Client desires to retain Consultant as an independent
contractor to provide Client the Services, and Client desires to be retained in,
said capacity, upon the terms and conditions hereinafter set forth;

                  NOW THEREFORE, for and in consideration of the mutual promises
and covenants contained herein, and for other good and valuable consideration
the receipt and sufficiency of which is hereby acknowledged, the parties hereto
agree as follows:

         1. Engagement. Client, upon the terms and conditions set forth herein
engages Consultant to perform and render such services of an advisory or
consultative nature in order to inform the brokerage community, Client's
shareholders and the general public concerning financial public relations and
promotional matters relating to Client and its business. Consultant promises and
agrees to perform and render the Services upon the terms and conditions set
forth herein and any and all such necessary, convenient and incidental work and
services required to provide said Services on a "best efforts" basis.

         2. Scope of Consultant's Services. It is the intention of the parties
that Consultant will gather readily available and known public information
relating to Client and confer with the officers and directors of Client in an
effort to consolidate the information obtained into a summary form for
dissemination to interested parties. It is further intended that Consultant will
then distribute such information concerning Client to registered representatives
of broker-dealers and other persons, legal and natural, whom Consultant
determines, in its sole discretion, are capable of effectively disseminating
such information to the general public. Consultant shall not provide any
investment advice or recommendations, either express or implied, regarding
Client to any third parties; rather, Consultant will focus on contacting
persons and entities, generally via telephone communications, print media, and
person-to-person meetings, in order to familiarize said third parties with the
information concerning Client which Consultant has collected and is otherwise
available to the general public. Consultant shall not disseminate any
information concerning client without the express written authorization of
Client. Consultant agrees to submit written drafts of any and all such
information to the Client for Client's review and comment prior to dissemination

<PAGE>

by Consultant. Client agrees to diligently review each such draft on a timely
basis, to expeditiously provide written comments to Consultant and to authorize
the release of such information by Consultant when deemed appropriate by Client
in its sole and absolute discretion. Under no circumstances shall Client
authorize the dissemination of any information by the Consultant that contains
any misstatement of a material fact or that omits to state any material fact
that is necessary to make any of the statements made, in light of the
circumstances under which they are made, not misleading.

         3. Independent Contractor. Consultant agrees to perform the Services
pursuant to this Agreement as an independent contractor, according to its own
manner and methods not inconsistent with the provisions herein, and without
direction and control of Client. Consultant, solely and exclusively, will
employ, direct, supervise, discharge, and fix the compensation, working
conditions and practices of its employees, be responsible for their payment and
will comply with all laws relating to such payment of employees. Consultant will
provide, at its sole expense, Employer's Liability and Workers' Compensation
insurance for all of its employees together with any other form of insurance
required by law to be provided for the protection of its employees. Further,
Consultant, solely and exclusively, shall be responsible for paying all taxes,
including insurance and contributions for social security and unemployment, and
self-employment taxes, which are measured by wages, salaries, or other
renumerations paid to Consultant's owners, directors, officers, shareholders,
employees, agents, or representatives, levied under existing laws, rules, or
regulations. Consultant, solely and exclusively, shall be responsible for, and
shall exercise complete control of its employees in all matters, disputes or
grievances arising out of or in any way connected with Consultant's operations.

         4. Third Party Work of Consultant. Although Consultant may choose to
only perform work solely for Client for a defined period, nothing contained
herein shall be interpreted or construed, expressly or by implication, as
preventing Consultant from entering into similar agreements with others, or
holding itself out to the public as available to engage in such agreements with
others. Consultant shall notify Client of its performance of consulting services
for third parties which could conflict with Consultant's obligations under this
Agreement. Upon receiving such notice from Consultant, Client may terminate this
Agreement by notice in writing or consent to Consultant's outside consulting
activities. Client's failure to terminate this Agreement shall constitute
Client's ongoing consent to Consultant's outside consulting activities.

         5. Term of Agreement. This Agreement shall be in full force and effect,
unless earlier terminated pursuant to the termination provisions provided
herein, for an initial term of six (6) months commencing July 15, 1998 and
terminating January 14, 1999. This Agreement may be extended for additional
renewal terms of six (6) months each upon such terms as may be agreed between
the parties in writing.

         6. Time, Place and Manner of Performance. Consultant shall be available
for advice and counsel to the officers and directors of Client at such
reasonable and convenient times and places as may be mutually agreed upon in
writing between the parties. Notwithstanding the foregoing, Consultant shall, in
its sole discretion, allocate the amount of time required to provide any
specific service to Client.

<PAGE>

       IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed in several counterparts, by their respective, corporate,
partnership or business officers or owners, as the case may be, thereunto duly
authorized, as of the day and year first written above.

PERFORMANCE STRATEGIES, INC.                    STEROIDOGENESIS INHIBITORS INC.

By: /s/ Charles E. Jordan                       By: /s/ Alfred Sapse
   ------------------------------                  ----------------------------
   Charles E. Jordan, President                 Dr. Alfred Sapse, President

                                                SUBJECT TO BOARD
                                                OF DIRECTORS APPROVAL

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00002-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00002-of-00352.parquet"}]]